Invimestrocel - Athersys
Alternative Names: Allogeneic stem cell therapy - Athersys; AMI MultiStem; HLCM 051; MultiStem; PF-05285401; PF-5285401Latest Information Update: 05 Nov 2023
At a glance
- Originator Athersys
- Developer Armed Forces Radiobiology Research Institute; Athersys; Case Western Reserve University; Healios; University of Texas Health Science Center at Houston
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - SARS-CoV-2 acute respiratory disease
Highest Development Phases
- Phase III Stroke
- Phase II/III SARS-CoV-2 acute respiratory disease
- Phase II Adult respiratory distress syndrome; Graft-versus-host disease; Multiple organ failure; Myocardial infarction
- Preclinical Acute radiation syndrome; Heart failure; Peripheral arterial disorders
- No development reported Brain injuries; Multiple sclerosis; Spinal cord injuries; Transplant rejection
- Discontinued Diabetes mellitus; Mucopolysaccharidosis I; Parkinson's disease; Ulcerative colitis
Most Recent Events
- 10 Oct 2023 Athersys suspends a phase III MASTERS-2 trial in Stroke in the USA and Taiwan (IV, Infusion) due to company intends to conduct additional data analysis with independent statisticians (NCT03545607)
- 10 Oct 2023 Invimestrocel licensed to Healios worldwide for the treatment of Adult respiratory distress syndrome
- 18 May 2023 Athersys plans clinical trials with Multistem for Adult-respiratory-distress-syndrome and COVID-2019-infections